Norway, March 20 -- Oncoinvent, a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces that the China National Intellectual Property Administration (CNIPA) has granted a new patent for Radspherin[(R)], the Company's lead product candidate, marking the first approval worldwide within this patent family.The newly granted patent covers a key technical development to optimize Radspherin's[(R)] performance, specifically the size-controlled calcium carbonate microparticle technology. With this grant, patent protection for Radspherin[(R)] in China is expanded in scope and duration, with a term extending to 2041. This...